Research programme: targeted immunotherapies - Kleo Pharmaceuticals

Drug Profile

Research programme: targeted immunotherapies - Kleo Pharmaceuticals

Alternative Names: Antibody recruiting molecules - Kleo Pharmaceuticals; ARMs - Kleo Pharmaceuticals; SyAMS - Kleo Pharmaceuticals; Synthetic antibody recruiting molecules - Kleo Pharmaceuticals

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Yale University
  • Developer Kleo Pharmaceuticals
  • Class Immunotherapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Infections

Most Recent Events

  • 01 Sep 2016 Kleo Pharmaceuticals and Biohaven Pharmaceuticals enter into a clinical development master service agreement for the development of targeted immunotherapies including Antibody Recruiting Molecules and Synthetic Antibody Recruiting Molecules
  • 01 Sep 2016 Targeted immunotherapies involving Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics licensed to Kleo Pharmaceuticals worldwide
  • 01 Sep 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top